1. Academic Validation
  2. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling

miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling

  • Biomed Pharmacother. 2018 Mar;99:278-285. doi: 10.1016/j.biopha.2018.01.055.
Qingwei Wu 1 Yingying Zhao 1 Peihua Wang 2
Affiliations

Affiliations

  • 1 Department of Otolarynglogy Head & Neck Surgery, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639th on Huangpu District Manufacturing Bureau Road, Shanghai, 200011, China; Ear Institute Shanghai Jiaotong University School of Medicine.
  • 2 Department of Otolarynglogy Head & Neck Surgery, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639th on Huangpu District Manufacturing Bureau Road, Shanghai, 200011, China; Ear Institute Shanghai Jiaotong University School of Medicine. Electronic address: [email protected].
Abstract

This study aims to investigate the roles of miR-204 in tumor angiogenesis of head and neck squamous cell carcinoma (HNSCC). Here, we found that miR-204 level was reduced in HNSCC tissues relative to that in normal adjacent tissues. Overexpression of miR-204 promoted tumor angiogenesis in HNSCC cells. Mechanistically, JAK2 was identified as a direct target of miR-204, and miR-204 overexpression blocked JAK2/STAT3 pathway. Moreover, overexpression of JAK2 attenuated the inhibition of miR-204 on tumor angiogenesis of HNSCC. Furthermore, overexpression of miR-204 enhanced sensitivity of cetuximab in HNSCC cells, this effect was attenuated by JAK2 overexpression too. Importantly, JAK2 expression was negatively correlated with miR-204 level in HNSCC tissues. Therefore, miR-204 acts as a tumor suppressor by blocking JAK2/STAT3 pathway in HNSCC cells.

Keywords

miR-204 JAK2/STAT3 tumor angiogenesis head and neck squamous cell carcinoma cetuximab.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18960
    99.56%, JAK2 Inhibitor
    JAK